Back to Journals » International Journal of Nanomedicine » Volume 14

Nanomedicine-based formulations containing ω-3 polyunsaturated fatty acids: potential application in cardiovascular and neoplastic diseases

Authors Serini S, Cassano R, Trombino S, Calviello G

Received 8 December 2018

Accepted for publication 21 February 2019

Published 23 April 2019 Volume 2019:14 Pages 2809—2828


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Thomas J. Webster

Simona Serini,1,2,* Roberta Cassano,3,* Sonia Trombino,3 Gabriella Calviello1,2

1Institute of General Pathology, Università Cattolica del Sacro Cuore, 00168 Roma, Italy; 2Fondazione Policlinico Universitario A, Gemelli 00168 Roma, Italy; 3Department of Pharmacy, Health and Nutritional Sciences, Università della Calabria, 87036 Cosenza, Italy

*These authors contributed equally to this work

Abstract: Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) are dietary factors involved in the prevention of cardiovascular, inflammatory, and neoplastic diseases. A multidisciplinary approach – based on recent findings in nutritional science, lipid biochemistry, biotechnology, and biology of inflammation and cancer – has been recently employed to develop ω-3 PUFA-containing nanoformulations with an aim to protect these fatty acids from degradation, increase their bioavailability and delivery to target tissues, and, thus, enhance their bioactivity. In some cases, these nanoformulations were designed to administer ω-3 PUFAs in combination with other nutraceuticals or conventional/innovative drugs. The aim of this strategy was to increase the activities of the compounds contained in the nanoformulation and to reduce the adverse effects often induced by drugs. We herein analyze the results of papers evaluating the potential use of ω-3 PUFA-containing nanomaterials in fighting cardiovascular diseases and cancer. Future directions in this field of research are also provided.

Keywords: innovative biotechnologies, cardiovascular diseases, nanoparticles, ω-3 PUFAs, cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]